67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Recruiting

Phase 1

Phase 2

67Cu-SARTATE™67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Sponsor:

Clarity Pharmaceuticals Ltd

Code:

NCT04023331

Conditions

Neuroblastoma

Relapsed Neuroblastoma

Refractory Neuroblastoma

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

67Cu-SARTATE

64Cu-SARTATE

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-17. This information was provided to ClinicalTrials.gov by Clarity Pharmaceuticals Ltd on 2024-07-08.